# Efficacy of Galantamine to Treat Schizophrenia

> **NCT00232349** · PHASE4 · TERMINATED · sponsor: **Seattle Institute for Biomedical and Clinical Research** · enrollment: 21 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorder

## Interventions

- **DRUG:** galantamine

## Key facts

- **NCT ID:** NCT00232349
- **Lead sponsor:** Seattle Institute for Biomedical and Clinical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study terminated due to no apparent benefit.
- **Last updated:** 2008-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232349, "Efficacy of Galantamine to Treat Schizophrenia". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00232349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*